Description

SYNOPSIS WORKSHEET NIH-NOI-26-PCA-NIA-01589 NAICS 541380 - TESTING LABORATORIES AND SERVICES PSC Q301 – Reference Laboratory Testing This is a Notice of Intent (NOI). This notice is published in accordance with Federal Acquisition Regulation (FAR) 5.101(a)(1) requiring the dissemination of information regarding proposed contract actions. This is a Notice of Intent to award a sole source, firm-fixed price purchase order under the authority of 41 U.S.C. 3304(a)(1), as implemented by FAR 13.106-1(b) and 13.501(a)- Only One Responsible Source and No Other Supplies or Service Will Satisfy Agency Requirements and is not a request for quotes. The National Institutes of Health (NIH) intends to negotiate on an other than full and open competition to the maximum extent practicable consistent with the agency's minimum needs. For this acquisition, however, full and open competition is not contemplated. The acquisition is being conducted under the authority of 41 U.S.C. § 3304(a)(1), as implemented by FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Based on the market research conducted, Banner Sun Health is the only known source capable of providing the required NULISA protein analysis services together with the established and validated quality control (QC) bridging cohort necessary to meet the Government's minimum needs. The Government's requirement is not limited to routine NULISA assay execution. It includes the ability to support: Longitudinal analytical consistency across assay runs, batches, and study periods; Assessment and correction of analytical drift; Normalization of datasets generated over time; and Harmonization of current project data with future datasets and external collaborators. Banner Sun Health is uniquely qualified because it already maintains a dedicated, validated, matrix-matched, dynamic-range-qualified, and biobanked NULISA QC bridging cohort designed specifically for these purposes. No other known source was identified that could provide this capability immediately and without substantial duplication of cost, unacceptable delay, and unacceptable risk to scientific validity and data integrity. The Period of Performance shall consist of one (1) twelve-month base period and two (2) twelve-month option periods, as follows: Base Period: 8/1/2026 – 7/31/2027 Option Period One: 8/1/2027 – 7/31/2028 Option Period Two: 8/1/2028 – 7/31/2029 Services shall be performed in Bethesda, MD. The NIH Intramural Center for Alzheimer's Disease and Related Dementias (CARD) is an interdisciplinary initiative dedicated to advancing the understanding, diagnosis, and treatment of Alzheimer's disease and related dementias. CARD supports translational and clinical research efforts designed to improve scientific knowledge of disease mechanisms and accelerate the development of effective diagnostic and therapeutic strategies. Biomarkers are central to this mission. They are essential …

Classification

Place of Performance

Contracting Office

Contacts

Attachments (1)

• Attachment 1